H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Cardiff Oncology to $14 from $12 and keeps a Buy rating on the shares. The Ccinical update from Phase 2 ONSEMBLE trial in 2L RAS-mutant metastatic colorectal cancer reinforced earlier data, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRDF:
- Cardiff Oncology price target raised to $7 from $5 at Piper Sandler
- Cardiff Oncology reports Q4 EPS (93c), consensus (28c)
- Cardiff Oncology provides update on discontinued ONSEMBLE trial data
- Cardiff Oncology Reports Progress in Colorectal Cancer Trials
- Cardiff Oncology doses first patient in CRDF-004 trial
